all report title image
  • Published On : Jan 2022
  • Code : CMI2631
  • Industry : Pharmaceutical
  • Pages : 162
  • Formats :

Immuno-oncology is an advanced approach to cancer treatment through encouragement of immune system. Immune checkpoint inhibitors is the most well-established immune-oncology agent, which has exceptional success results overall multiple malignancies, with many approvals.

There are still many challenges in managing the toxicities and ensuring that healthcare systems in oncology, even if the immuno-oncology agents are changing the quality for life with cancer rapidly.

Moreover, development of immune-oncology drugs covers a wide range of agents such as proteins, adjuvants, peptides, antibodies, bi-specific molecules, and cellular therapies.

India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to exhibit a CAGR of 13.1% during the forecast period (2021 -2028).

Figure 1. India Immuno-Oncology Drugs Market (US$ Mn), By Drug Type, 2021

India Immuno-Oncology Drugs  | Coherent Market Insights

Figure 1.1. India Immuno-Oncology Drugs Market (US$ Mn), By Drug Type, 2028

India Immuno-Oncology Drugs  | Coherent Market Insights

CMI table icon

India Immuno-Oncology Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 265 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 13.1% 2028 Value Projection: US$ 550 Mn
Geographies covered:
  • India
Segments covered:
  • By Drug Type: Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab, Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine), Cancer Vaccines (Gardasil, Cervarix)
  • By Cancer Type: Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, Others
  • By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies 
Companies covered:

Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited

Growth Drivers:
  • Rising incidence of cancer
  • Introduction of novel immuno-oncology therapies with lesser side effects
Restraints & Challenges:
  • High cost of immuno-oncology therapies
Opportunities:
  • Increasing government engagement to increase cancer diagnosis

Figure 2. India Immuno-Oncology Drugs Market (US$ Mn), By Cancer Type, 2021

India Immuno-Oncology Drugs  | Coherent Market Insights

Figure 2.1. India Immuno-Oncology Drugs Market (US$ Mn), By Cancer Type, 2028

India Immuno-Oncology Drugs  | Coherent Market Insights

The increasing developments and product launches are expected to drive the market growth over the forecast period.

For instance, researchers from Tata Centre for Technology and Design, IIT Bombay, are currently working on developing indigenous CAR T-cell therapy, affordable to cancer patients in the India.

India Immuno-Oncology Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The shutdown disrupted the supply, distribution, and manufacturing of medical supplies globally. Moreover due to social distancing, footfall in clinics and health institutions was observed which has led to a decrease in the number of surgical procedures, clinical trials, research and development activities, and others, which has negatively impacted the market growth.

As stated by National Cancer Institute, bacteria and viruses have potential role in development of cancer. Nearly 1 in 4 cases of cancer are infectious by virus in developed countries and 1 in 10 cases in undeveloped countries.

Being at high risk of COVID-19, the cancer patients are at highest risk from COVID-19 infection, such as utilization of ICU and invasive ventilation in comparison to non-cancer COVID-19 patients.

India Immuno-Oncology Drugs Market: Restraint

High cost of immuno-oncology therapies makes it unaffordable for population in the low- and middle-income class to opt for these therapies, which is expected to restrain growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody used for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high prices of oncology therapies, which cannot be afforded by patients with low income.

Key Players

Major players operating in the India immuno-oncology drugs market include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Immuno-Oncology also known as cancer immunotherapy, is a form of cancer treatment that utilizes immune system of the body to manage, prevent, and destroy cancer. Immuno-oncologists are growing and becoming a part of cancer care group by rapidly increasing the cancer care area. The researchers did study on how to attack cancer by the immune system. Some of them work in labs on creating new treatments and some of them interact between the immune system and cancer cells.

India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to increase to US$ 550 Mn by 2028, exhibiting a CAGR of 13.1% over the forecast period.

Market Dynamics

The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, increasing government engagement to increase cancer diagnosis, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Indian immuno-oncology drugs market over the forecast period.

According to the National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many people die every day due to tobacco-related cancer diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women, in 2018.

Moreover, The WHO also suggested that people with low and middle income countries should have necessary data for cancer policies because of lack of awareness for treatment availability.         

Key features of the study:

  • This report provides an in-depth analysis of the India immuno-oncology drugs market provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The India immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India immuno-oncology drugs market

Detailed Segmentation:

  • India Immuno-Oncology Drugs Market, Drug Type:
    • Immune Checkpoint Inhibitors
      • Nivolumab
      • Atezolimumab
      • Pembrolizumab
      • Durvalumab
    • Monoclonal Antibodies
      • Rituximab
      • Trastazumab
      • Bevacizumab
      • Nimotuzumab
      • Pertuzumab
      • Ado-Trastuzumab Emtansine
    • Cancer Vaccines
      • Gardasil
      • Cervarix
  • India Immuno-Oncology Drugs Market, Cancer Type:
    • Lung cancer
    • Blood cancer
    • Breast cancer
    • Ovarian cancer
    • Cervical cancer
    • Colorectal cancer
    • Stomach cancer
    • Head & Neck cancer
    • Others
  • India Immuno-Oncology Drugs Market, Distribution Channel:
    • Online Pharmacies
    • Retail Pharmacies
    • Hospital Pharmacies
  • Company Profiles:
    • Amgen, Inc. *
      • Company highlights
      • Product Portfolio
      • Key Highlights
      • Financial performance
      • Strategies
    • Hoffmann-La Roche AG.
    • Intas Pharmaceuticals Ltd.
    • AstraZeneca plc
    • Mylan N.V.
    • Reddy's Laboratories
    • Bristol - Myers Squibb
    • Merck & Co., Inc.
    • BIOCAD-Biotechnology company
    • Reliance Life Sciences
    • Biocon Limited
    • Hetero Drugs Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

India immuno-oncology drugs market is estimated to be valued at US$ 265 million in 2021 and is expected to exhibit a CAGR of 13.1% over the forecast period (2021-2028).
The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, and increasing government engagement to increase cancer diagnosis are the major factors, which are expected to drive the market growth over the forecast period. 
Immune checkpoint inhibitors segment is expected to hold a major market share over the forecast period.
Major factor hampering growth of the market include high cost of immuno-oncology therapies.
Major players operating in the market include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo